文献库 文献相关信息
- 题目:
- [Characteristics of cancer of the female reproductive organs as observed at the Gynecology-Obstetrical Department of the Osijek General Hospital].
- 作者:
- Milojković(M),Lederer(B),Pajtler(M)
- 状态:
- 发布时间1991-09-25 , 更新时间 2009-11-09
- 期刊:
- Jugosl Ginekol Perinatol
- 摘要:
- In the 1980-1989 period, 671 women were diagnosed with a malignant tumour of reproductive organs at the Department of Gynaecology, Cervical cancer proved most frequent, with 46.5% of the cases, followed by the cancer of the uterine body occurring in 29.5% of the patients. In 18.8% of the women, ovarian and oviductal cancer was diagnosed, whereas vulvar and vaginal cancer was found in 5.5% of the cases. There were 76.1% of the patients older than 50 years. Nulliparas suffered from ovarian and uterine body cancer significantly more often than from cervical cancer (t = 3.794; p less than 0.001, i.e. t = 2.974; p less than 0.001). However, terti- or multiparas had cervical cancer significantly more often than the cancer of ovaries or the uterine body (t = 3.711; p less than 0.001, i.e. t = 3.000; p less than 0.01). The first stage ovarian cancer was diagnosed in 15.0% of women only, whereas 37.1% of cervical and 78.3% of uterine body cancers were discovered at the first stage. At the time of diagnosis, the mean age of the patients with cervical cancer was 55.8 years, with ovarian cancer 57.9 years, with oviductal cancer 57.3 years, with uterine body cancer 60.8 years and with vulvar cancer 71.7 years. There were 34% of cervical cancer patients at the premenopausal age 15.5% with uterine body cancer and 27.5% of those suffering from ovarian cancer. The general five-year survival rate for patients suffering from the cancer of reproductive organs was 40.6%, i.e. 40.5% for cervical cancer, 54.7% for uterine body cancer, 23.4% for ovarian and oviductal cancer and 17.7% for vulvar or vaginal cancer. The total of 25% of the patients were lost from the evidence.
- 语言:
- hrv
- DOI:
DataTable pData
微信公众号
关注微信订阅号，实时查看信息，关注医学生物学动态。
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备13024435号-2
